Related news:
Blow for Reeves as AstraZeneca ditches PS450m investment - AstraZeneca rejected close to PS80mn in state support for cancelled Speke factory - AstraZeneca scraps £450m vaccine plant after Labour funding cut - AstraZeneca ditches plan to build PS450mn UK vaccine plant - AstraZeneca move leaves Reeves under the weather - Fresh blow for Rachel Reeves as AstraZeneca scraps PS450m investment in UK vaccine plant - Rachel Reeves accused of 'fumbling' AstraZeneca's PS450m vaccine plant plans - Covid-19 vaccines: Doctor's role in identifying AstraZeneca's concerning side effects - AstraZeneca overhauls management of its scandal-hit China division
AstraZeneca
Bookmark
ShareKey facts
- city: Cambridge
- country: United Kingdom
- sector: Health Care
- foundation year: 1999
- industry: Pharmaceuticals
- CEO: Pascal Soriot D.V.M., M.B.A.
- CEO gender: Male
Classified as: organization
Summary
AstraZeneca is a company. It is located in Cambridge, the United Kingdom and was founded in 1999. The company is part of the Health Care sector, specifically in the Pharmaceuticals industry.
Business
AstraZeneca is one of the 3,466,499 companies in our database.
- Assets: 105.4B $
- Debt: 31.4B $
- Employees: 83,100 people
- Free cash flow: 3.8B $
- Market cap: 184.7B $
- Profits: 112M $
- Revenues: 44B $
Companies from United Kingdom
Companies in the Pharmaceuticals industry
Companies in the Health Care sector
Stocks from AstraZeneca
Explore more on business
Talking Points:
- AstraZenecaResearchBased BioPharmaceutical Company
- AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
- We're transforming the future of healthcare by unlocking the power of what science can do. Community Guidelines: https://t.co/Kh08zUdFpT
- What science can do | AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation ...
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Learn more about talking points
